Document is current
Any future updates will be listed below
-
Authors
Ryoo, Seung-Bum https://orcid.org/0000-0001-6407-0444
Heo, Sunghoon
Lim, Yoojoo
Lee, Wookjae
Cho, Su Han https://orcid.org/0000-0001-5220-0352
Ahn, Jongseong
Kang, Jun-Kyu
Kim, Su Yeon
Kim, Hwang-Phill
Bang, Duhee
Kang, Sung-Bum
Yu, Chang Sik
Oh, Seong Taek
Park, Ji Won https://orcid.org/0000-0003-0046-8175
Jeong, Seung-Yong
Kim, Young-Joon
Park, Kyu Joo
Han, Sae-Won https://orcid.org/0000-0003-3275-431X
Kim, Tae-You
- License Information
-
More Information
Article History
Received: 3 November 2022
Revised: 25 April 2023
Accepted: 2 May 2023
First Online: 6 June 2023
Competing interests
: SH, YL, WL, SHC, JA, J-KK, SYK and H-PK are employees of IMBdx. DB owns stocks of IMBdx and Celemics. DB and S-WH received research funds and honoraria from IMBdx. T-YK is a founder of IMBdx. SH, WL, SYK, H-PK and T-YK are inventors on patent application (no. 10-2022-0038856, filed on March 29, 2022). The remaining authors declare no competing interests.
: This research was conducted in accordance with the Declaration of Helsinki in biomedical research involving human subjects. The Institutional Review Boards of all participating institutions approved the protocol (IRB number: H-1708-031-875), and written informed consents to allow research on their biospecimen were obtained from all participants before the collection of any clinical data or biospecimens.
: Not applicable.
